Solid Biosciences is trading 5.38% down now at $8.61, primarily amid weaker risk sentiment; no major company-specific announcement was identified for August 18, 2026.
- The latest substantive developments are the August 6 second-quarter update and potential $200 million stock offering filing, both predating the move.
- Nasdaq Composite futures are down 1.13% amid overnight geopolitical and bond-market concerns; this is a broader market explanation, not a confirmed company catalyst.